May

9

Chemokine Therapeutics

Filed Under Biotechnology & Drugs | Leave a Comment

Chemokine Therapeutics (Symbol: CHKT) is a product-focused biotechnology company that develops drugs that harness the therapeutic potential of stem cells through chemokine pathways.

Chemokines are a new class of cytokines, proteins which signal biological responses from stem cells that play a critical role in the growth, differentiation, and also maturation of cells necessary for fighting infection, as well as tissue repair and regeneration.

Stem cells are the master primitive cells that give rise to all of the cells and organs in the body. Chemokines are one of the major mediators of stem cell activity including stem cell growth, differentiation and maturation.

Being the leader in research in this field, the company currently has five products with two lead product candidates in clinical trials; CTCE-0214, for enhancing the immune system, and CTCE-9908, to prevent the spread of cancer and its continued growth.

Their main goal is to identify and develop multiple drug candidates for the treatment of cancer, blood disorders, cardiovascular and infectious disease.

Their recent press release states they had successfully reduced primary tumor growth in preclinical models of breast cancer with the treatment of the company’s CHCR4 antagonist and CTCE-9908.

In one study the investigators showed that mice treated with CTCE-9908 had statistically significant reduction of the primary tumor size compared to the control mice over time. At the 5-week and 6-week time points the mice treated with CTCE-9908 had an 86% decrease and 80% decrease in primary tumor growth compared to the control mice, respectively. In a second study, treatment with CTCE-9908 also demonstrated a statistically significant reduction in the rate of metastasis compared to the control group. At the 5-week and 6-week time points, the mice treated with CTCE-9908 had an 89% reduction and 95% reduction in metastatic tumor burden compared to the control mice, respectively.

Isn’t it exciting? Of course, at this moment they’re still far from their goal of creating a super drug that cures cancer. But it’s still pretty encouraging to see their recent experiment has turned out to be a tremendous success. For only 7 cents/share, this stock is definitely a bargain!

Quote of the Day:
My favorite time frame for holding a stock is forever. – Warren Buffett

  • Share/Bookmark

ss_blog_claim=15d8108b540c7f0a9f388810cf5ad68f ss_blog_claim=15d8108b540c7f0a9f388810cf5ad68f